Skip extra treatment for early lung cancer after surgery if no cancer found
Part of Cancer, Lungs & breathing clinical trials.
This study checks if people with early-stage non-small cell lung cancer can safely skip chemotherapy or radiation after surgery when repeated blood tests show no sign of cancer left. You would only be watched with regular scans and blood tests to make sure the cancer doesn't come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove all visible lung cancer and it was stage IB, II, or IIIA
- You are 18 or older
- Two different blood tests taken a while apart show no cancer DNA (called minimal residual disease, or MRD)
- You are expected to live at least 3 more months and are generally up and about (ECOG score 1 or 2)
- You agree to get a blood test and imaging every 3 months for 2 years after surgery
- You have not had chemotherapy, radiation, or other cancer treatment before this trial, and you have not had another cancer in the last 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether it is safe to skip routine radiation to the tumor bed in patients with stage III lung cancer that has responded well to immunotherapy and chemotherapy. It aims to reduce side effects while still controlling the cancer.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This study tests whether a simple blood test (liquid biopsy) can help doctors monitor for cancer returning after surgery for early-stage lung cancer. It is for people with non-small cell lung cancer that can be removed with surgery.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This trial uses a blood test to look for tiny bits of cancer DNA after treatment. It may help find early signs that lung cancer has come back, so doctors can act sooner.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.